Antioxidant synthetic peptides counteracting hyperglycaemia induced endothelial cell dysfunction

Colin E. Murdoch, Elena De Falco (Lead / Corresponding author)

Research output: Contribution to journalEditorialpeer-review

105 Downloads (Pure)


In the issue of International Journal of Cardiology, Hemling P. et al. describe that the impairment of thioredoxin (TRX) activity is partially responsible for reactive oxygen species (ROS) accumulation in hyperglycaemic endothelial cells (EC). Interestingly, authors extend this finding to placental arterial EC where the employment of TRX synthetic peptides is able to restore physiological levels of ROS and subsequent improvement of the VEGF-A response, which is diminished in diabetic conditions [1]. The article sheds light on the biological impact of TRX-based as a link between the redox systems and endothelial function in hyperglycaemia.
Original languageEnglish
Pages (from-to)82-83
Number of pages2
JournalInternational Journal of Cardiology
Early online date23 Mar 2020
Publication statusPublished - 1 Jun 2020

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Antioxidant synthetic peptides counteracting hyperglycaemia induced endothelial cell dysfunction'. Together they form a unique fingerprint.

Cite this